CytomX Therapeutics, Inc.

CTMXNASDAQHealthcare● Active

$2.94

$-0.06(-2.00%)

Market Cap$472821175

P/E Ratio—

52W High$8.21

52W Low$1.72

Avg Volume6.9M

Open$3.05

Beta2.09

Free Cash Flow Financials Revenue

CytomX Therapeutics, Inc. (CTMX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CTMX · free cash flow · updated Jun 8, 2026

Core FCF metrics

CTMX · FCF · TTM · margin & CAGR

Free cash flow was −$75.8M for FY2025 (fiscal year ending 2025-12-31), up 12.4% year-over-year The FCF margin was -99.5%.

FY2025 Free Cash Flow−$75.8M▲ +12.4% YoY

Trailing 12M (TTM)−$80.2Mtrailing 4 quarters sum

FCF Margin-99.5%−$75.8M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CTMX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$75.6M(0M)−$75.8M▲ +12.4%-99.5%

FY2024−$86.2M(0M)−$86.5M▼ 52.2%-62.7%

FY2023−$56.0M(1M)−$56.9M▲ +49.5%-56.2%

FY2022−$110.8M(2M)−$112.5M▲ +6.7%-211.7%

FY2021−$119.0M(2M)−$120.6M▼ 4189.5%-323.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CTMX · P/FCF · FCF yield · FCF per share

CytomX Therapeutics, Inc. (CTMX) reported negative free cash flow of −$0.08B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CTMX · cash flow statement · operating / investing / financing

For FY2025, CytomX Therapeutics, Inc. generated −$75.6M in operating cash flow and spent 0M in capital expenditures, yielding −$75.8M in free cash flow.

Operating Activities

−$75.6M

Cash from core business operations

2025-12-31

Investing Activities

−$59.7M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$110.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$75.6M) − |CapEx| (0M) = FCF (−$75.8M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CTMX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

CytomX Therapeutics, Inc.YOU

CTMX

−$75.8M+12.4%-99.5%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

CytomX Therapeutics, Inc. (CTMX) reported free cash flow of −$75.8M for FY2025 (fiscal year ending 2025-12-31), up 12.4% year-over-year. The FCF margin was -99.5%.

Based on available data, CytomX Therapeutics, Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $168.8M in FY2017.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CTMX free cash flow · 8 questions

CytomX Therapeutics, Inc. free cash flow was −$75.8M for FY2025, up 12.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$80.2M.

CTMX free cash flowCTMX FCFCTMX FCF 2025CTMX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · CytomX Therapeutics, Inc. · CytomX Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026